Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Sadif Analytics Prime
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

China Resources Double-Crane Pharmaceutical Co Ltd Receives Drug Permission


Thursday, 25 Jul 2013 08:00pm EDT 

China Resources Double-Crane Pharmaceutical Co Ltd announced that it has received drug permission for its edaravone bulk pharmaceutical chemicals (permission number: H20130053) and edaravone injection (permission number: H20130051), from State Food and Drug Administration. Edaravone is used to relief the symptoms of acute cerebral infarction. 

Company Quote